Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease, to be presented at ...
Lundbeck to present phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson’s disease at the 2026 AD/PD conference: Valby, Denmark Tuesday, ...
Lundbeck Advances Parkinson's Research With New Phase 1B Data At AD/PDTM 2026. Phase 1b data on Lu AF28996, an investigational treatment for people with advanced Parkinson's disease, to be presented ...
Detailed price information for Alterity Therapeutics Ltd (PRNAF) from The Globe and Mail including charting and trades.
An acclaimed Aussie chef has passed away following a two year fight against a rare illness.
Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for “Madison Mid Cap Fund”. A ...
A cross-complaint comes as a second Be Well mental health campus is set to open in Irvine. Nonprofit leaders deny the ...
Lundbeck announces last patient randomized ahead-of-schedule in phase 3 MASCOT clinical trial: Valby, Denmark Wednesday, March 11, 2026, 13:00 Hrs [IST] H. Lundbeck A/S (Lundbeck) ...
The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results